The effect of Orexin receptor antagonist Suvorexant on REM sleep behavior disorder

The effect of Orexin receptor antagonist Suvorexant on REM sleep behavior disorder - The effect of Suvorexant on RBD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027333

Enrollment

Registered

2017-05-15

Start date

2017-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

REM sleep behavior disorder

Interventions

Double blind pracebo control study of Suvorexanat from February 23, 2018. Pracebo conditions are: One week drug-free including antidepressant and Clonazepam. One night polysomnography at sleep laborat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: International Classification of Sleep Disorders - Third Edition (ICSD-3). For a diagnosis of REM sleep behavior disorder

Exclusion criteria

Exclusion criteria: another sleep disorder, mental disorder, medication, or substance use. Subjects are excluded when %RWA is less than 30 under placebo conditions.

Design outcomes

Primary

Measure	Time frame
The decrease of muscle tone on REM sleep	—

Countries

Japan

Contacts

Public ContactTakuro Endo

Sleep clinic Chofu Medical devision

takuro@sleep-t.com0424900700

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026